Background: Low dose oral Folinic acid was used together with uracil with ftorafur (UFT) producing some response with low toxicity in advanced colorectal cancer. However, the 28 day regimen produced 20 per cent severe (grade III, IV) diarrhea. This study required 21 days' treatment to evaluate the response rate and toxicity in advanced colorectal cancer.

Method: UFT 300 mg/m2/day together with oral Folinic acid 7.5 mg/dose for 21 days with 7 days rest were required to treat 28 cases of recurrent or metastatic colorectal cancer.

Results: Partial response was seen in 13.6 per cent of 22 evaluable cases and minimal response seen in 18.2 per cent. The majority (77%) of these patients had previously been treated with 5-fluorouracil (5-FU). These results are comparable to other studies. Toxicity was low with 3.3 per cent grade III, IV diarrhea.

Conclusion: This regimen produced some activity in metastatic colorectal cancer with low toxicity.

Download full-text PDF

Source

Publication Analysis

Top Keywords

oral folinic
12
folinic acid
12
advanced colorectal
12
colorectal cancer
12
uracil ftorafur
8
low dose
8
dose oral
8
low toxicity
8
toxicity advanced
8
regimen produced
8

Similar Publications

Effects of Shenqi Xiangyi granules in advanced gastric cancer chemotherapy.

World J Gastrointest Oncol

January 2025

Department of Oncology, Zhangjiagang First People's Hospital, Suzhou 215600, Jiangsu Province, China.

Background: Owing to the absence of specific symptoms in early-stage gastric cancer, most patients are diagnosed at intermediate or advanced stages. As a result, treatment often shifts from surgery to other therapies, with chemotherapy and targeted therapies being the primary options for advanced gastric cancer treatment.

Aim: To investigate both treatment efficacy and immune modulation.

View Article and Find Full Text PDF

We describe the utility of 'folic and folinic acid load tests' in the investigation of a 26-year-old woman with persistently low serum folate and moderate hyperhomocysteinaemia unresponsive to folic acid supplements. Serum folate, plasma 5-methyltetrahydrofolate (5-MTHF), red cell 5-MTHF and plasma total homocysteine at baseline, 2-h, 4-h and 2- or 4-days (if applicable) post administration of a large dose of oral folic acid, or oral or parenteral folinic acid were measured. The tests confirmed non-compliance but also suggested an unsuspected possible defect in the folate pathway based on differential response to folic versus folinic acid supplements.

View Article and Find Full Text PDF

Purpose: The management of rectal adenocarcinoma has evolved during the last decade, shifting from a conventional neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy in all cases to a total neoadjuvant approach, especially in locally advanced tumors when a sphincter-sparing surgery has been planned. However, the exact indications and the neoadjuvant regimen with the highest response remain unresolved. We aimed to assess whether administering neoadjuvant chemotherapy before and after preoperative chemoradiotherapy could increase the pathological complete response (pCR) rates.

View Article and Find Full Text PDF

The folate cycle has been implicated in the pathophysiology of autism due to its role in the glutathione oxidative stress pathway, amino acid and DNA methylation reactions, and neurotransmitter synthesis pathway. Previous research on folinic acid supplementation in autistic children has suggested potential benefits. The primary aim of this pilot study was to determine the safety, feasibility and efficacy of oral folinic acid in improving communication and behaviour in autistic children.

View Article and Find Full Text PDF
Article Synopsis
  • Methotrexate is a key medication for treating childhood cancers like acute lymphoblastic leukemia but can lead to severe side effects such as neurotoxicity, specifically leukoencephalopathy, which usually presents with gradual neurological symptoms.
  • A case involving a 10-year-old boy showed acute neurological symptoms, including limb weakness and involuntary movements, after taking oral methotrexate, a rare occurrence compared to traditional administration routes like injection.
  • MRI scans revealed brain abnormalities consistent with methotrexate-induced neurotoxicity, highlighting the need for careful monitoring of neurological effects even with oral use of the drug.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!